ÂÜÀòÂÒÂ×

Adam Watson, PhD, is a biotechnology entrepreneur and scientist, currently serving as Co-Founder and CEO of MeCo Diagnostics, a venture-backed startup focused on developing predictive biomarker tests for antifibrotic drug repurposing in early-stage breast and prostate cancer patients. In addition to this role, Adam holds positions as an Entrepreneur in Residence at EvoNexus and as a Grants Reviewer for Genome Canada. Adam's prior experience includes roles as a Scientist at Lynx Biosciences, Inc., and Associate Scientist at Hawkeye Spectral Imaging LLC, along with a postdoctoral fellowship at the University of Arizona College of Medicine, where a multivariate prognostic biomarker for breast cancer was clinically validated. Adam Watson earned a PhD in Cancer Biology from the University of Arizona and a B.Sc. in Microbiology from the University of Victoria.